Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 29 n° 341

Posts Tagged ‘cancer’

Juno Therapeutics to Present at November 2017 Investor Conferences

Posted by fidest press agency su mercoledì, 8 novembre 2017

cancerJuno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in November. The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development.
Juno will present at the 26th Annual Credit Suisse Healthcare Conference at 9:15 a.m. Mountain Time (MT) on Wednesday, November 8, 2017.
Juno will present at the Evercore ISI Biopharma Catalyst / Deep Dive Conference at 8:45 a.m. Eastern Time (ET) on Wednesday, November 29, 2017.
The webcasts will be accessible on the Investor Relations page of Juno’s website at A replay of each presentation will be available at the same location for 30 days following the corresponding conference.
Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates

Posted by fidest press agency su giovedì, 2 novembre 2017

tumore metastatico1Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune and infectious diseases based on rationally designed consortia of human microbiome-derived bacteria, today announced that it has exclusively sub-licensed key intellectual property from JSR Corporation to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics. These live biotherapeutics have been shown to activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy. The sub-licensed intellectual property is based on the pioneering research of Dr. Kenya Honda, Professor, of Keio University School of Medicine and his collaborators in the University of Tokyo in Japan. An IND filing for the lead product candidate is planned in 2018.“Dr. Honda’s research suggests an entirely new approach to cancer immunotherapy harnessing the human microbiome, which has the potential to significantly enhance the effectiveness of cancer therapies,” said Bernat Olle, PhD, Chief Executive Officer of Vedanta Biosciences. “We are actively developing product candidates containing defined bacterial consortia that activate CD8+ T cells and stimulate the immune system to fight cancer alone and in combination with checkpoint inhibitors. This license to additional intellectual property from Dr. Honda’s institution further strengthens Vedanta’s leading IP position in the microbiome field.” In validated pre-clinical models of cancer, Vedanta’s orally administered product candidates containing defined bacterial consortia induced CD8+ T cells, potentiating the immune system’s attack of tumor cells. The tumor fighting effects of a variety of checkpoint inhibitors were significantly amplified when combined with the bacterial consortia, suggesting a potentially novel approach for combination cancer immunotherapy.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients

Posted by fidest press agency su lunedì, 30 ottobre 2017

PhiladelphiaPhiladelphia. Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today preliminary data from an ongoing Phase 1a/b clinical trial with its lead oral investigational agent, RGX-104. These data demonstrate immune-stimulatory activity in solid tumor patients with highly-refractory malignancies, including patients who have failed prior checkpoint inhibitors. Also presented were pre-clinical data establishing the immune-modulatory and anti-tumor effects of RGX-104. The company presented the data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia. RGX-104 is a liver X receptor (LXR) agonist that upregulates the expression of the target gene, Apolipoprotein E (ApoE), triggering several downstream effects via ApoE receptors. In pre-clinical data presented today, treatment with RGX-104 in mouse models resulted in dual effects on myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs), both innate immune cells that play a central role in regulating anti-tumor immunity and response to checkpoint inhibitors. Innate immune activation with RGX-104, coupled with a reduction in tumor blood vessels, resulted in anti-tumor activity as a monotherapy as well as synergy with checkpoint inhibitors (CPI) in several drug-resistant mouse models. These data provide rationale for Rgenix’s ongoing Phase 1a/b trial of RGX-104 in advanced cancer patients and support evaluation of RGX-104 as both a monotherapy as well as in combination with CPIs.
As part of the ongoing Phase 1a/b clinical trial, 15 patients with a variety of solid tumors have been treated with escalating doses of RGX-104 monotherapy. Patients treated with RGX-104 had a median of six prior therapies with a range of 1-12, highlighting a population of patients with profoundly resistant disease.Activation of the LXR-ApoE pathway with oral administration of RGX-104 was associated with immune-stimulatory activity in 9 of 10 evaluable patients. This was demonstrated by an increase (up to 11-fold) in activated circulating PD-1+CD8+ T cells during treatment. T cell activation was observed in patients who experienced modulation of the innate immune system during treatment. The effect of RGX-104 on the innate immune system consisted of both MDSC depletion (up to 95% decrease) as well as DC activation as indicated by induction of PD-L1 expression (up to 100% increase). In most cases these effects were observed within two weeks of treatment initiation and generally preceded the onset of T cell activation.
Safety data demonstrate good tolerability with on-target safety findings in the first three dosing cohorts. One patient experienced a DLT of grade 4 reversible neutropenia – a known potential effect of LXR agonism – that reversed within one week, allowing the patient to subsequently tolerate a 50% dose reduction. No MTD has been reached to date. Stable disease has been observed in 4 of 12 evaluable patients, including three who have failed prior checkpoint inhibitor therapy, for periods of at least 8 weeks.Rgenix plans to enroll subsequent dose-escalation cohorts of the RGX-104 monotherapy trial in Q4 2017. Additionally, Rgenix is planning to initiate the Phase 1b expansion component of the study, comprised of disease directed cohorts receiving RGX-104 monotherapy as well as cohorts receiving RGX-104 combined with a CPI, projected to begin in 1H 2018.The LXR-ApoE pathway was discovered as a cancer target using a microRNA (miRNA) based target discovery approach originally developed at The Rockefeller University and now exclusively licensed to Rgenix.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy of SpaceOAR

Posted by fidest press agency su venerdì, 29 settembre 2017

prostateResearchers have long known that higher radiation doses (dose escalation) are more effective at killing tumors. However, the amount of radiation safely delivered to the prostate is limited by the rectum proximity, and concerns of creating long-term rectal injury and associated side effects. Physicians at the University of Texas Southwestern Medical Center and Memorial Sloan Kettering Cancer Center recently evaluated 44 men receiving SpaceOAR Hydrogel followed by dose-escalated (45 Gray) SBRT. The data show that SpaceOAR Hydrogel significantly reduces rectal injury in men undergoing high-dose SBRT for prostate cancer. Specifically, 13.6 percent of treated men had rectal mucosal injury in the study, all of which were mildly symptomatic and completely healed within six months following treatment. These findings are significant, as prior clinical research found that 90 percent of non-SpaceOAR Hydrogel patients treated with the same SBRT regimen experienced similar radiation-induced mucosal injury due to higher rectal wall radiation doses. None of the patients exhibited signs of biochemical cancer recurrence in the 12-month follow up period.“Hypofractionated approaches are gaining momentum in the treatment of prostate cancer, and in our experience, high-dose regimens have provided exceptionally high rates of biochemical control, but at the cost of an increased risk of rectal complications associated with the rectal wall dose,” said Michael Folkert, MD, radiation oncologist and brachytherapy specialist at University of Texas Southwestern Medical Center in Dallas. “Our new study demonstrates that use of the perirectal hydrogel spacer gets us the ‘room’ we need to safely deliver the most potent therapeutic doses to patients, which may ultimately lead to the optimal cancer control while significantly reducing the risk of treatment related complications.” As the first and only prostate cancer spacing device to receive Food and Drug Administration (FDA) clearance, SpaceOAR Hydrogel is placed between the prostate and rectum, protecting the rectum and surrounding tissue from high-dose radiation exposure. Long-term clinical data has shown that at both three and five years post-radiation therapy (using Intensity Modulated Radiation Therapy), patients treated with SpaceOAR Hydrogel demonstrated significant bowel, urinary and sexual function benefits.1-3
“We are excited by the successful results from this study, as it is the first time we’ve evaluated SpaceOAR Hydrogel in prostate cancer patients treated with high-dose SBRT, and the findings confirm a significant clinical benefit,” said John Pedersen, CEO, Augmenix. “As this robust data indicates – along with the other positive data on our hydrogel spacing technology presented this week at ASTRO – we remain steadfast in our vision to develop disruptive medical technology that improves the lives of patients receiving radiation therapy.”Prior SpaceOAR Hydrogel clinical studies have demonstrated significant reductions in long-term radiation side effects, and improvements in patient quality of life following the delivery of standard prostate radiation doses. This recent study was designed to see if SpaceOAR Hydrogel allows for safe prostate dose escalation, which if proven safe in other studies, has the potential to reduce cancer recurrence rates following prostate radiotherapy.For more information on SpaceOAR Hydrogel, visit (photo: prostate)

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Treatment of heart attack patients depends on history of cancer

Posted by fidest press agency su mercoledì, 20 settembre 2017

cuoreSophia Antipolis Treatment of heart attack patients depends on their history of cancer, according to research published today in European Heart Journal: Acute Cardiovascular Care. The study in more than 35 000 heart attack patients found they were less likely to receive recommended drugs and interventions, and more likely to die in hospital if they had cancer than if they did not. “It is well known that cancer patients may have an increased risk of cardiovascular disease as a result of their treatment,” said senior author Dr Dragana Radovanovic, head of the AMIS Plus Data Centre in Zurich, Switzerland. “However, on the other hand, little is known about the treatment and outcomes of cancer patients who have an acute myocardial infarction.”This study investigated whether acute myocardial infarction patients with a history of cancer received the same guideline recommended treatment and had the same in-hospital outcomes as those without cancer.The study included 35 249 patients enrolled in the acute myocardial infarction in Switzerland (AMIS Plus) registry between 2002 and mid-2015. Of those, 1 981 (5.6%) had a history of cancer.Propensity score matching was used to create two groups of 1 981 patients each – one with cancer history and one without – that were matched for age, gender, and cardiovascular risk factors.The researchers compared the proportions of patients in each group who received specific immediate drug therapies for acute myocardial infarction, and percutaneous coronary intervention (PCI) to open blocked arteries. They also compared the rates of in-hospital complications and death between the two groups. The researchers found that cancer patients underwent PCI less frequently (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.67–0.88) and received P2Y12 blockers (OR, 0.82; 95% CI 0.71–0.94) and statins (OR, 0.87; 95% CI, 0.76–0.99) less frequently. In-hospital mortality was significantly higher in patients with cancer than those without (10.7% versus 7.6%; OR, 1.45; 95% CI, 1.17–1.81).Patients with a history of cancer were more likely to have complications while in hospital. They had 44% higher odds of cardiogenic shock, 47% higher chance of bleeding, and 67% greater odds of developing heart failure than those with no history of cancer.Dr Radovanovic said: “Patients with a history of cancer were less likely to receive evidence-based treatments for myocardial infarction. They were 24% less likely to undergo PCI, 18% less likely to receive P2Y12 antagonists and 13% less likely to receive statins. They had also more complications and were 45% more likely to die while in hospital.”“More research is needed to find out why cancer patients receive suboptimal treatment for myocardial infarction and have poorer outcomes,” continued Dr Radovanovic.
“Possible reasons could be the type and stage of cancer, or severe comorbidities. Some cancer patients may have a very limited life expectancy and refuse treatment for myocardial infarction,” she added.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , | Leave a Comment »

Protecting workers: stricter limits on cancer-causing substances

Posted by fidest press agency su sabato, 2 settembre 2017

europeNew EU rules to protect workers from carcinogens and mutagens in the workplace were voted in by the Employment Committee. The legislation, approved by 42 votes in favour, none against and 8 abstentions and already informally agreed with EU Ministers, sets EU-wide rules to eliminate and reduce all carcinogens and mutagens in workplaces.Employers will have to assess the risk of exposure for workers and take preventive measures. This should tackle the primary cause of work-related deaths in the EU, i.e. cancer. The aim is to help save up to 100 000 lives over the next 50 years.It includes a lower “occupational exposure limit (OEL)”, i.e. a maximum quantity of harmful substances that workers can be exposed to, for:
· chromium VI, used in textile dyes, paints and leather tanning materials and generated during the casting, welding or cutting of stainless steel
· hardwood dust, produced, for instance, by cutting or pulverising wood
· vinyl chloride monomer, mainly used to produce PVC
MEPs ensured that the Commission will have to assess the possibility of including reprotoxic substances, i.e. those having effects on sexual function and fertility, by the first quarter of 2019.New rules also establish that the national authority responsible for the health surveillance of workers can decide that health surveillance must continue after the end of exposure, for as long as needed to safeguard health.
For chromium VI, a limit value of 0,010 mg/m3 will be in place for the first 5 years after the date on which it is applicable in national law, subsequently lowered to 0,005 mg/m3 afterwards. A derogation for welding, plasma cutting or similar processes puts a limit of 0.025 mg/m3 for the first 5 years and 0,005 mg/m3 thereafter.For hard wood dust, a limit is set at 3 mg/m3 for five years after the entry into force of the directive and is thereafter lowered to 2 mg/m3. The Parliament will put the draft directive to the final vote during one of forthcoming plenaries.

Posted in Estero/world news, Politica/Politics | Contrassegnato da tag: , , , | Leave a Comment »

International Forum on Cancer Patients Empowerment “Shared decisions, one policy”

Posted by fidest press agency su giovedì, 11 maggio 2017

università studi milanoMilano, 16 al 17 maggio 2017 presso l’Università degli Studi. Nella sessione di apertura dalle 9.30 alle 10.15 sono attesi gli interventi del Ministro della Salute, Beatrice Lorenzin, e del Ministro dell’Istruzione, dell’Università e della Ricerca, Valeria Fedeli. L’equilibrio tra innovazione e sostenibilità, in uno scenario caratterizzato dai nuovi trend dell’oncologia di precisione e della medicina genica e personalizzata, sarà al centro di una
successiva sessione dedicata (dalle 11.45 alle 13.30), dove interverranno tra gli altri, Mario Melazzini, Presidente dell’Agenzia Italiana del Farmaco, Massimo Scaccabarozzi, Presidente di Farmindustria, e Nathalie Moll, EFPIA General Director. Nella giornata del 17 maggio, Gianluca Vago, Rettore dell’Università degli Studi di Milano introdurrà la sessione di apertura, in cui Paolo Corradini, Direttore del Dipartimento di Oncologia ed Onco-ematologia dell’Ateneo milanese, illustrerà l’esperienza maturata negli anni da quello che oggi, con oltre 60 addetti, si propone come un centro di eccellenza, tra i più grandi a livello europeo, dedicato alla ricerca e cura oncologica. Il Forum avrà luogo presso l’Università degli Studi di Milano, sede di importanti gruppi di ricerca operanti nel contesto e partecipe di molti dei più rilevanti programmi di ricerca nazionali e internazionali sul fronte della ricerca scientifica e su quello del trasferimento tecnologico e di sviluppo applicativo dei risultati della ricerca scientifica. La partecipazione dei cittadini ai processi decisionali rappresenta uno dei valori fondamentali su cui si basa la strategia comunitaria europea, anche nella pianificazione dei nuovi programmi sanitari. “Shared decisions, one policy” è il primo Forum internazionale dedicato ai diritti dei pazienti e al loro attivo coinvolgimento nel processo decisionale clinico e nelle politiche di sanità pubblica nell’era dell’oncologia personalizzata, con particolare riferimento alle esigenze di omogeneizzazione e riequilibrio tra i diversi standard assistenziali europei.
Il Forum propone una sintesi multidisciplinare e multidimensionale, offrendo il contributo di tutte le categorie a vario titolo interessate e coinvolte su questo tema in Italia e in Europa: rappresentanti dei pazienti, operatori sanitari, politici, legislatori e regolatori, organizzazioni internazionali, organismi governativi e aziende farmaceutiche. Il Forum contribuisce al dialogo internazionale sul diritto umano ad uno stato ottimale di salute, collocandosi a pieno titolo all’interno del contesto dell’azione comune europea sul controllo del cancro.
La partecipazione al Forum non prevede costi di iscrizione ed è aperta a tutti gli interessati, previa registrazione sul sito: (foto: università studi milano)

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

International Forum on Cancer Patients Empowerment

Posted by fidest press agency su venerdì, 21 aprile 2017

porta nuova milanoMilano 16 e 17 maggio a Milano l’International Forum on Cancer Patients Empowerment, primo appuntamento promosso su questo tema a livello europeo.
Nella sessione di apertura il 16 maggio dalle 9.30 alle 10.15 sono attesi gli interventi del Ministro della Salute, Beatrice Lorenzin, e del Ministro dell’Istruzione, dell’Università e della Ricerca, Valeria Fedeli. L’equilibrio tra innovazione e sostenibilità, in uno scenario caratterizzato dai nuovi trend dell’oncologia di precisione e della medicina genica e personalizzata, sarà al centro di una successiva sessione dedicata (dalle 11.45 alle 13.30), dove interverranno tra gli altri, Mario Melazzini, Presidente dell’Agenzia Italiana del Farmaco, Massimo Scaccabarozzi, Presidente di Farmindustria, e Nathalie Moll, EFPIA General Director. Nella giornata del 17 maggio, Gianluca Vago, Rettore dell’Università degli Studi di Milano introdurrà la sessione di apertura, in cui Paolo Corradini, Direttore del Dipartimento di Oncologia ed Onco-ematologia dell’Ateneo milanese, illustrerà l’esperienza maturata negli anni da quello che oggi, con oltre 60 addetti, si propone come un centro di eccellenza, tra i più grandi a livello europeo, dedicato alla ricerca e cura oncologica.
Il concetto di patient empowerment, coniato e sviluppatosi negli Stati Uniti a partire dagli anni ’70, ha segnato una vera e propria rivoluzione nel mondo della salute. Un cambiamento culturale, che ha posto il paziente al centro del processo di cura, con la sua storia personale, il suo vissuto, il suo ambiente, la sua rete di relazioni. E’ stato dimostrato, infatti, che la consapevolezza del paziente rispetto alle proprie condizioni di salute e al proprio percorso di cura incida positivamente sull’esito delle terapie e porti benefici alla collettività in termini di risparmio e maggiore efficienza del Sistema. Per questo, l’empowerment del paziente oncologico si pone oggi come riferimento imprescindibile e unificante delle politiche a livello globale: la partecipazione dei pazienti ai processi decisionali è uno dei valori fondamentali su cui si basa la pianificazione delle nuove strategie sanitarie dell’UE. I pazienti europei sono chiamati ad essere più coinvolti in ogni aspetto della loro salute, dal rimodellamento della sperimentazione clinica alla legislazione e in tutte le questioni che li riguardano in prima persona, compresa quella della gestione dei dati genetici, al centro dei nuovi protocolli della medicina personalizzata.
Troppo spesso, tuttavia, il “patient empowerment” resta ancora relegato a una dichiarazione di intenti e raramente tradotto nella prassi medica e sanitaria quotidiana. “Shared decisions, one policy” è il titolo scelto per questo primo Forum, che affronterà la sfida di tradurre in azioni concrete e buone pratiche la centralità del paziente oncologico, grazie al ruolo chiave che può essere giocato dalla sinergia tra scienza e formazione. Con questo obiettivo, l’evento vedrà il contributo di tutti gli attori coinvolti nel Sistema (rappresentanti dei pazienti, operatori sanitari, politici, legislatori, regolatori, organizzazioni internazionali, organismi governativi e aziende farmaceutiche) per fare il punto sui traguardi raggiunti e tracciare una roadmap per affrontare esigenze e sfide future.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Nuove prospettive dell’immuno-oncologia

Posted by fidest press agency su giovedì, 8 dicembre 2016

tumore metastaticoVienna. Ogni giorno in Italia si registrano più di 110 diagnosi di tumore del polmone, complessivamente nel 2016 sono stimati 41.300 nuovi casi nel nostro Paese. Il 60-70% è individuato in fase avanzata, oggi per questi pazienti si stanno aprendo importanti prospettive nel trattamento in prima linea grazie alla combinazione delle molecole immuno-oncologiche innovative. Lo dimostrano i risultati presentati alla 17° Conferenza mondiale sul tumore del polmone dell’International Association for the Study of Lung Cancer in corso a Vienna. “L’immuno-oncologia – sottolinea il prof. Federico Cappuzzo, direttore Oncologia all’Ospedale di Ravenna – ha già evidenziato risultati decisivi in seconda linea nella fase avanzata della malattia. La sfida ora è individuare i pazienti che possono maggiormente beneficiare di questa nuova arma in prima linea, cioè al momento della diagnosi. Sono incoraggianti i risultati aggiornati dello studio CheckMate -012, dopo un follow-up di circa 16 mesi, sulla combinazione di nivolumab e ipilimumab nella forma non a piccole cellule, la più frequente. I tassi di risposta obiettiva confermata in tutti i pazienti trattati sono pari al 43%, quasi il doppio rispetto alla percentuale registrata con nivolumab in monoterapia (23%). Inoltre, la sopravvivenza a un anno copre il 100% dei pazienti quando l’espressione tumorale di PD-L1 è superiore al 50%. Positivi anche i dati sulla sopravvivenza libera da progressione. Per questi pazienti si sta sempre più concretizzando la possibilità di evitare la chemioterapia e aver accesso a farmaci innovativi caratterizzati da una tollerabilità migliore. Nel frattempo aspettiamo i risultati di CheckMate -227, questo studio di fase III in cui l’Italia ha svolto un ruolo determinante sta valutando le combinazioni con nivolumab in prima linea: riteniamo che il futuro sia rappresentato dall’associazione delle molecole immuno-oncologiche”. Il principale fattore di rischio di questa neoplasia è rappresentato dal fumo, un vizio sempre più diffuso fra le donne: infatti il 23% delle italiane è tabagista. Con gravi conseguenze: tra il 1999 e il 2011 l’incidenza del carcinoma del polmone è diminuita del 20,4% tra gli uomini, mentre è aumentata del 34% nelle donne. La percentuale di sopravvivenza a 5 anni delle persone colpite da carcinoma del polmone in Italia è pari al 14,3%, più elevata rispetto alla media europea (13%). Le possibilità di guarigione cambiano drasticamente in relazione allo stadio in cui avviene la diagnosi. Complessivamente, la sopravvivenza a 5 anni nella forma non a piccole cellule in stadio I è compresa tra il 47% e il 50%, mentre per lo stadio IV scende al 2%. I tassi tendono a essere più bassi nel tumore del polmone a piccole cellule perché questa forma cresce più rapidamente (in stadio I sono compresi tra il 20 e il 40%, in stadio IV scendono all’1%). “Lo studio CheckMate -032 presentato a Vienna – spiega il prof. Francesco Grossi, Responsabile UOS Tumori Polmonari all’IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro di Genova – ha valutato nivolumab in monoterapia e in combinazione con ipilimumab in pazienti precedentemente trattati, quindi in seconda linea, colpiti proprio da tumore del polmone a piccole cellule. Il tasso stimato di sopravvivenza a due anni è stato del 30% con nivolumab più ipilimumab e del 17% con nivolumab in monoterapia. Non solo. Il tasso di risposta obiettiva con la combinazione era pari al 25%, il doppio di quello riportato con la monoterapia (11%). È la conferma che la combinazione rappresenta la strada da seguire”.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Sabato e domenica la quarta tappa del primo tour nazionale WALCE con test della spirometria gratuiti

Posted by fidest press agency su sabato, 3 ottobre 2015

sigaretteUna sigaretta gigante campeggerà per tutto il weekend in via VIII febbraio 1848: una struttura alta 3 metri e lunga 14, con all’interno un vero e proprio percorso multimediale di prevenzione e informazione sui danni arrecati dal fumo e test spirometrico gratuito. “Esci dal tunnel. Non bruciarti il futuro” approda domani nel centro storico di Padova, quarta tappa (dopo Torino, Bari e Milano) del tour nazionale di sensibilizzazione sul tumore al polmone organizzato da WALCE Onlus (Women Against Lung Cancer in Europe), l’associazione europea dedita ai pazienti affetti dalla neoplasia e ai loro familiari. “Abbiamo lanciato il progetto in occasione della Giornata Mondiale senza Tabacco e dopo aver incontrato i cittadini, i media e le istituzioni di Torino, Bari e Milano, siamo qui a Padova, a fianco delle Istituzioni, per ribadire con forza quanto sia importante la prevenzione e quali sono i gravi danni causati dal fumo, attivo e passivo – spiega la prof.ssa Silvia Novello, presidente di WALCE Onlus e docente nel Dipartimento di Oncologia Polmonare presso l’Università di Torino. L’iniziativa sarà inaugurata sabato mattina alle 10.00 con il taglio del nastro, e proseguirà fino a domenica pomeriggio. Tutte le attività sono gratuite e aperte al pubblico dalle 10 alle 19 nelle due giornate: si parte dal totem posacenere in ingresso, si passa al desk per l’esame spirometrico, si può parlare con lo pneumologo e con l’oncologo e ricevere opuscoli informativi e gadget. “Le malattie respiratorie correlate al tabacco sono in sensibile aumento in tutte le fasce d’età, anche tra i non tabagisti: – spiega il prof. Pierfranco Conte, coordinatore tecnico scientifico della Rete Oncologica Veneta – irritazione a occhi e naso, mal di testa, secchezza della gola, vertigini, nausea, tosse e malattie respiratorie più gravi come la bronchite cronica o la bronco-pneumopatia ostruttiva. Inoltre, respirare sigarette, proprie e altrui, determina il 90% del totale dei decessi per tumore del polmone, che nel 2014 ha colpito 40mila persone”. La campagna ha il patrocinio di AIOM (Associazione Italiana di Oncologia Medica), Fondazione Insieme Contro il Cancro, Healthy Foundation, AIPO (Associazione Italiana Pneumologi Ospedalieri), dell’Ordine dei Medici Chirurghi e Odontoiatri della Provincia di Bari, della Società Italiana di Chirurgia Toracica (SICT), della Rete Oncologica Veneta, dell’Istituto Oncologico Veneto IRCCS di Padova e del Comune di Padova – Città Sane. “Il fumo fa male è una verità dimostrata e l’assunzione costante e prolungata nel tempo di tabacco incide sulla durata della vita media – sottolinea il vicesindaco di Padova, Eleonora Mosco – E’ necessario sensibilizzare l’opinione pubblica sui rischi connessi al tabagismo. L’invito pertanto che rivolgo a tutti coloro che sono ostaggio di questo brutto e deleterio vizio, è di smettere di fumare, per se stessi e per gli altri. Mi rivolgo in particolare ai tantissimi giovani che negli ultimi anni, secondo i sondaggi, sono accaniti consumatori di tabacco sfuso, più economico delle sigarette. Il compito di tutti noi è dunque quello di tenere alta l’attenzione su questo tema di vitale importanza per la salute, puntando sulla prevenzione universalmente riconosciuta come l’arma più efficace nella lotta a tante patologie. Come Amministrazione sosteniamo con orgoglio il progetto Esci dal tunnel, non bruciarti il futuro, che farà tappa a Padova questo week-end ringraziando gli oncologi e pneumologi che scenderanno in piazza contro i danni del fumo”.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Contro melanoma, cautela al sole e tempi brevi per farmaci

Posted by fidest press agency su martedì, 3 aprile 2012

Ripetuti eccessi di esposizione ai raggi solari durante l’infanzia triplicano il rischio di sviluppare il melanoma da adulti. Per questo motivo i bambini vanno difesi dal sole con adeguate protezioni, evitando sempre le ore centrali della giornata, soprattutto con l’arrivo della bella stagione. Ma alla prevenzione si aggiungono nuove strumenti di cura efficaci per combattere questo tumore, immunoterapia e farmaci mirati su bersagli cellulari. Se ne è parlato al convegno nazionale dell’Associazione italiana di oncologi a medica (Aiom) intitolato Nuove frontiere nel trattamento del melanoma, tenutosi a Napoli. Oggi, infatti, si stanno affacciando nuove armi realmente efficaci, come l’immunoterapia che agisce stimolando le difese immunitarie contro le cellule tumorali con importante beneficio per i malati. Inoltre sono in via di registrazione anche in Italia farmaci mirati su bersagli cellulari da impiegare nei pazienti con melanoma metastatico che presentano specifiche alterazioni molecolari. I tempi tra la registrazione europea e la successiva approvazione dei nuovi farmaci in Italia sono purtroppo ancora lunghi. Gli oncologi chiedono che vengano velocizzati i processi registrativi per i trattamenti oncologici realmente innovativi come nel caso del melanoma. «La battaglia contro questa forma di cancro è difficile» spiega il professor Carmine Pinto, segretario nazionale Aiom «ma si può vincere ponendo più attenzione a semplici regole di prevenzione. Troppe persone si e spongono al sole senza precauzioni, in particolare i bambini rappresentano l’anello debole della catena. Un richiamo da tenere in considerazione soprattutto in questi mesi, in cui molti approfittano del fine settimana per prendere un po’ di colore. Vanno inoltre totalmente bandite le lampade abbronzanti che, secondo l’Agenzia internazionale per la ricerca sul cancro (Iarc), aumentano il rischio di melanoma del 75%, al pari del fumo di sigaretta, se utilizzate prima dei 30 anni». (fonte farmacista33)

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Nordion Launches Custom Doses for TheraSphere® Liver Cancer Therapy in Europe and Canada

Posted by fidest press agency su lunedì, 26 marzo 2012

Ottawa, Canada (PRNewswire) Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in Europe and Canada for TheraSphere®, Nordion’s Y-90 microsphere treatment for liver cancer. Nordion has also filed a request with the Food and Drug Administration for approval of the custom dose feature in the United States.In addition to standard dose vial configurations, Nordion now offers an expanded range of TheraSphere treatment options with custom doses available in wider variety of increments. The custom doses are designed to provide greater treatment flexibility for physicians, save administration time and reduce product waste, while limiting unnecessary radiation exposure to patients and healthcare professionals.Nordion has also enhanced its Treatment Window Illustrator tool to demonstrate how custom doses can be selected and compared to standard dose vial configurations.Nordion is attending the Society of Interventional Radiology (SIR) Annual Scientific Meeting 2012, March 24-29, in San Francisco. Nordion representatives will be at Booth #1234 to talk about TheraSphere to physicians attending the conference. Nordion will host two “Eat and Be Educated” learning sessions at its booth:
TheraSphere is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive yttrium-90 (Y-90). The product is injected by physicians into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow. In the US, TheraSphere is used to treat patients with unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and can be used as a bridge to surgery or transplantation in these patients. It is also indicated for the treatment of HCC patients with portal vein thrombosis (PVT). TheraSphere is approved by the U.S Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has more than 500 highly skilled employees in three locations. Find out more at and follow us at

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Experts Meet to Drive Improvements in Cancer Treatment in Europe

Posted by fidest press agency su lunedì, 19 marzo 2012

"seeds" used for brachytherapy of pr...

Image via Wikipedia

Copenhagen, (PRNewswire). Clinicians come together in Copenhagen to discuss the best approaches for future brain, prostate and lung cancer radiotherapy treatment. Today clinicians from around the world will gather at the 4th Brainlab European Radiotherapy User Meeting to share their best practice and experiences in treating difficult-to-treat cancers using advanced radiotherapy The two-day meeting held at the Global Center of Stereotactic Radiotherapy at Rigs Hospitalet, Copenhagen University Hospital, Denmark, aims to discuss the best approaches for future radiation treatment to achieve the best outcomes for patients. Over 170 clinicians from nearly 90 different international cancer centres will hear 33 different advanced approaches for treating cancers across the body using modern radiation therapy techniques. Highlights of the meeting will be keynote presentations on new protocols for the treatment of lung, prostate and brain cancers with radiosurgery. These protocols will show that radiosurgery can offer faster treatment times, shorter periods of treatment and in turn allows greater numbers of patients to be treated using the same advanced radiotherapy systems. Prostate Cancer clinical specialist Professor Raymond Miralbell, Head of Radiation Oncology at University Hospital Geneva, Switzerland, will present his experiences treating prostate cancer using a novel radiosurgery approach. Brainlab’s bi-annual Radiotherapy meeting immediately follows the launch of the Global Center of Stereotactic Radiotherapy at Rigs Hospitalet, launched to local clinicians the previous day. The facility is one of the most well equipped cancer centers worldwide with advanced technology that allows clinicians to both treat and research some of the most modern techniques available to patients.
Brainlab develops, manufactures and markets software-driven medical technology that supports targeted, less-invasive treatment. Core products are image-guided systems and software that provide real-time information used for surgical navigation and radiosurgical planning and delivery.Brainlab technology drives collaboration between hospitals and clinicians from a wide variety of subspecialties-from neurosurgery and oncology to orthopedics, ENT, CMF and spine and trauma. This integration delivers better access to improved and more efficient treatment.Founded in 1989, the privately held Brainlab group has more than 5,000 systems installed in over 80 countries. Based in Munich, Germany, Brainlab employs 1020 people in 17 offices worldwide.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

‘Cancer Drug Market Will Reach $75 Billion in 2012’ visiongain Report Predicts

Posted by fidest press agency su martedì, 28 febbraio 2012

London (PRNewswire) A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. Visiongain is a business information provider based in London, UK.The new study predicts that overall revenues for anti-cancer treatments will increase strongly from 2012 to 2022. Individual drugs will benefit too. Roche will continue to be the leading company in the cancer-treating drugs market throughout the study’s forecast period. Through emerging technologies and increasing demand in developed and developing countries, the future of cancer treatments holds great promise. That revenue growth will be mainly owing to the worldwide increase in cancer incidence and prevalence. New opportunities for cancer treatment exist, with high sales likely from many drugs – small-molecule products and biological agents (biologicals) – to 2022. Also, R&D pipelines in oncology are strong, including those for monoclonal antibodies (MAbs).The visiongain pharmaceutical industry analyst at visiongain, said, “Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs. There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients’ lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine.”

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

European Medicines Agency Approves Orphan Medicinal Product Application of DCPrime’s Acute Myeloid Leukemia Vaccine

Posted by fidest press agency su giovedì, 2 febbraio 2012

Bone marrow aspirate showing acute myeloid leu...

Image via Wikipedia

Amsterdam Biotechnology company DCPrime today announces that the Committee for Orphan Medical Products (COMP) of the European Medicines Agency has issued a positive opinion recommending DCPrime’s application for orphan drug designation of, the company’s dendritic cell-based cancer vaccine candidate, which targets Acute Myeloid Leukemia (AML).”This orphan drug designation is a major step in DCPrime’s work towards approval of our AML vaccine, and clearly reflects the COMP’s view of the potential of this vaccine in improving survival of patients with AML”, said DCPime’s CEO and CSO Dr. Ada Kruisbeek. “At the present time, AML patients lack an approved therapy to prevent the cancer from returning after standard chemotherapy. In 75% of the patients treated, the leukemia returns within 2 years. Our vaccine is intended as a therapy to prevent the cancer from coming back, and in our current clinical study we are establishing if we can delay or prevent AML from returning. If we succeed, this will improve survival outcomes in AML.”
Orphan drug designation is granted to products aimed at treatment of a rare disease or condition that affects fewer than 5 per 10,000 people in the European Community. As a result, DCPrime will be eligible to receive a number of benefits, including fee reduction, valuable scientific advice to optimize development and guidance on clinical design, and extended allowance for marketing exclusivity after the drug’s approval for a period of up to ten years.
DCPrime is a Dutch clinical stage company, dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne™. With this platform, the company can generate off-the-shelf DC-based vaccines for a broad range of cancer types. DCOne™-based DC vaccines share all immune-stimulatory properties with patient derived DC-based vaccines, and have the simple logistics of off-the-shelf products. DCPrime’s lead product DCP-001 is in the clinic in a Phase I/IIa study in patients with Acute Myeloid Leukemia (AML).

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Cancro: importante scoperta

Posted by fidest press agency su martedì, 16 agosto 2011

Clare Hall Manor, Ridge. Part of the London Re...

Image via Wikipedia

Gli scienziati del britannico Institute of Cancer Research hanno scoperto come le cellule cancerose siano in grado di “muoversi” trasformandosi in tumori, offrendo importanti spunti per la messa a punto di nuovi farmaci per prevenirne la diffusione. Una notizia che secondo Giovanni D’Agata, componente del Dipartimento Tematico Nazionale “Tutela del Consumatore” di Italia dei Valori e fondatore dello “Sportello dei Diritti”, non deve rimanere circoscritta al ristretto mondo della scienza, ma dev’essere conosciuta anche dai profani, affinché la ricerca stessa sia spronata nell’incessante studio per debellare questa grande piaga che incombe sull’umanità. I ricercatori sono convinti di aver identificato una proteina denominata “JAK” che aiuta le cellule tumorali generando la forza necessaria a muoversi. Come è noto, infatti, quando il cancro si sviluppa, con il noto processo chiamato metastasi, diventa molto più difficile da trattare, tanto che si pensa che il 90% delle morti conseguenti a tumori si verifichi dopo il sorgere delle metastasi. Gli scienziati dell’istituto di ricerca britannico, che hanno indagato sulle sostanze chimiche coinvolte nella migrazione cellulare nel melanoma – il famigerato cancro della pelle – sostengono che i processi venivano controllate dalla stessa sostanza chimica ossia la stessa molecola, chiamata “JAK”. La molecola “JAK” non è un nome nuovo tra le molecole studiate come “colpevoli” nei processi legati allo svilupparsi tumori. La stessa proteina è stata già presa di mira dagli scienziati nella lotta alla leucemia, tant’è che sono già allo studio alcuni farmaci che sono già in fase di sviluppo. Lo studio in questione ha rivelato che tali farmaci potrebbero anche arrestare la diffusione del cancro ed hanno pensato di effettuare già nei prossimi anni studi clinici per verificare se questi agenti potranno fermare la diffusione delle cellule tumorali nel corpo umano. Secondo il dottor Lesley Walker, direttore del Cancer Research UK, quella in corso sarà una sfida gigantesca nel trattamento del cancro che servirà ad impedirne la diffusione in tutto il corpo e a mantenerlo a bada una volta già diffuso.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Melanoma: terapie innovative

Posted by fidest press agency su giovedì, 9 giugno 2011

Importanti passi in avanti nel trattamento del melanoma, un tumore della pelle particolarmente aggressivo che ogni anno nel nostro Paese fa registrare 7000 nuove diagnosi e 1500 decessi. Ipilimumab, un nuovo anticorpo monoclonale sviluppato da Bristol-Myers Squibb, associato al trattamento chemioterapico tradizionale, la dacarbazina, ha dimostrato di migliorare in maniera significativa la sopravvivenza dei pazienti colpiti da questo tumore nella forma metastatica. I dati, pubblicati anche sulla prestigiosa rivista scientifica “New England Journal of Medicine”, sono stati presentati ieri pomeriggio in sessione plenaria al 47° Congresso ASCO (American Society of Clinical Oncology), il più importante congresso mondiale di oncologia in corso a Chicago fino al 7 giugno, con la partecipazione di oltre 30.000 specialisti. La ricerca, che analizza per la prima volta la sopravvivenza a tre anni, ha coinvolto 500 persone colpite da melanoma metastatico e non trattate prima con altre terapie. A un anno sopravvive il 47,3% dei pazienti trattati con la combinazione costituita da ipilimumab associato alla dacarbazina rispetto al 36,3% di quelli trattati con il chemioterapico tradizionale; a 24 mesi il 28,5% contro il 17,9%, a tre anni il 20,8% contro il 12,2%. Si tratta di un risultato mai raggiunto prima. Con la terapia standard la sopravvivenza media è infatti di 6-9 mesi a cinque anni.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Phase III for Orazol (TM)

Posted by fidest press agency su mercoledì, 17 novembre 2010

Dublin, Ireland, (Globe Newswire) — After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol™. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA’s abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer. If approved, this drug would provide a new treatment, which could improve prognosis, in combination with existing treatments, for early stage breast cancer patients. Merrion has been focused on an oral form of this drug (zoledronic acid) for the bone metastases indication. However this trial would expand Orazol’s potential by allowing Orazol to be used for early treatment of breast cancer in addition to bone metastases for late stage cancer patients. Zoledronic acid has been shown to improve Disease Free Survival in large-scale Phase III clinical studies, involving thousands of breast cancer patients.  Merrion has previously received scientific advice from the Committee for Medicinal Products for Human Use (CHMP) agreeing the approval pathway for Orazol in Europe for the existing bone metastases indication. Following a licensing agreement, Merrion would seek agreement from the CHMP to expand the use of Orazol to earlier stage breast cancer treatment.
Orazol, Merrion’s lead product, is a unique tablet formulation of zoledronic acid, made possible by Merrion’s proprietary GIPET® technology, and for which there are issued US Orazol patents to 2027. Orazol provides an ideal product profile to address the market needs, as a well-tolerated tablet formulation with weekly dosing.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Ca prostata, meno decessi con la terapia trimodale

Posted by fidest press agency su mercoledì, 28 aprile 2010

La terapia combinata trimodale (Cmt) a base di brachiterapia, radioterapia esterna e soppressione androgenica riduce il rischio di mortalità per carcinoma prostatico, rispetto alla sola brachiterapia, in uomini anziani a elevato rischio di questo tumore, senza problemi cardiovascolari o corretti mediante chirurgia. È quanto concludono, in uno studio pubblicato su Cancer, alcuni ricercatori del Department of radiation oncology, Brigham and Women’s hospital and Dana-Farber Cancer Institute di Boston. All’indagine hanno preso parte 764 uomini, d’età pari o superiore a 65 anni, a elevato rischio di tumore alla prostata che sono stati sottoposti alla sola brachiterapia o alla terapia combinata. I partecipanti non avevano mai subito infarto del miocardio oppure, dopo episodi infartuali, erano stati trattati mediante impianto di stent oppure intervento chirurgico. Dopo un follow-up medio di 4,9 anni, sono deceduti 25 uomini per cancro alla prostata. Effettuate le opportune correzioni per età e fattori prognostici per questo tumore, il rischio di mortalità è apparso molto più basso dopo l’esposizione a Cmt che dopo brachiterapia (hazard ratio = 0,29). Tra i fattori associati a un aumento del rischio di decesso è stato individuato un punteggio di Gleason compreso tra 8 e 10. «Aggressivi trattamenti loco-regionali sono, quindi, da suggerire in anziani sani a elevato rischio di cancro prostatico» conclude Hoffman KE, principale autore dello studio. Cancer. 2010 Mar 22. [Epub ahead of print] (fonte doctor news)

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

To treat chronic lymphocytic leukemia

Posted by fidest press agency su giovedì, 13 agosto 2009

Copenhagen, Denmark Genmab A/S (OMX: GEN) announced top-line results from the Phase II study of Arzerra(TM) (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients. A total of 61 patients were treated in the study. Treatment response was assessed using the 1996 National Cancer Institute Guidelines. The complete remission rate was 32% in patients who received 500 mg of ofatumumab (n=31) and 50% in patients who received 1000 mg of ofatumumab (n=30). The overall response rate was 77% in the 500 mg treatment group and 73% in the 1000 mg treatment group.There were no unexpected safety findings reported during treatment and within 30 days after last infusion. The most common adverse event reported was neutropenia at 48%. Other common adverse events (greater that 15 percent) were nausea, leukopenia, rash, vomiting, pyrexia, headache and thrombocytopenia. The number of patients, who experienced adverse events, including serious adverse events, was similar between the two dose groups. One death was reported and was judged by the investigator as unrelated to ofatumumab. Patients in this open label study were randomized into two treatment groups. Each patient was to receive one infusion of 300 mg of ofatumumab in combination with FC followed by 5 monthly infusions of either 500 or 1000 mg of ofatumumab in combination with FC. Disease status was measured every 4 weeks until week 24 and every 3 months thereafter until disease progression or 24 months. Treatment response was assessed according to the 1996 National Cancer Institute Working Group guidelines by an Independent endpoints Review Committee. Patients nothaving progressed on their disease at 24 months will be followed for disease progression at 6 month intervals until 60 months.The objective of the study was to determine the efficacy of ofatumumab in combination with FC in previously untreated CLL patients. The primary endpoint was complete remission rate from start of treatment until 3 months aftelast infusion. Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells. This epitope is different from the binding sites targeted by other CD20 antibodies currently available.The CD20 molecule is a key target in CLLtherapy because it is expressed on most B-cells in CLL patients. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country Genma is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »